ClinicalTrials.gg
TerminatedNCT03339037TBIPEDUpdated Apr 22, 2026

Hyperbaric Oxygen Therapy Effect on Post Concussion Syndrome in Children

An interventional study of Hyperbaric oxygen therapy and Normobaric air SHAM in Hyperbaric Oxygen Therapy, Traumatic Brain Injury and Post-Concussion Syndrome, sponsored by Assaf-Harofeh Medical Center. Terminated at 1 site in Israel. Open to participants aged 8 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Primary conditionPost-Concussion SyndromeRegistry: Brain Injuries, TraumaticReclassifiedWhy we changed it
Registry
Brain Injuries, Traumatic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Concussion Syndrome
Why
  1. The study's listed conditions name Post-Concussion Syndrome, a narrower term within Brain Injuries, Traumatic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assaf-Harofeh Medical Center · Not applicable, Interventional, and Treatment

Why this study was terminated
Recruitment difficulties - patients refusal to sham controlled
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
8 Years to 16 Years
Sex
All
01

Study summary

Due its high incidence, mTBI and its consequences of PPCS are a major public health issue. There is no consensus regarding the treatment of PPCS in pediatrics. Relying on its results in adults, HBOT offers a promising new direction of treatment, which targets the basic pathological processes responsible for post-concussion symptoms.

The effect of hyperbaric oxygen therapy in pediatric TBI has never been evaluated.

The aim of the current study is to evaluate in a prospective cross-over, randomized study, the effect of HBOT on children with PPCS due to mild TBI.

Read the detailed description

The study is designed as a prospective, randomized, controlled, cross-over two groups trial. The study will be conducted in the -Sagol center for hyperbaric medicine and research and the children neurological unit of Assaf Harofeh Medical Center, Israel. Brain MRIs evaluation will be done the radiology department of Assaf-Harofeh Medical Center, Israel.

Study will include 70 patients After signing the informed consent (signed by the parents), patients will undergo computerized cognitive tests using the computerized Neurotrax and Moxo cognitive batteries. Patients who fulfill inclusion criteria will be included in the study.

After signing informed consent (by parents, at the prescreening phase), patients who fill inclusion criteria, will be randomized in 1:1 manner into the treated or the control-cross group. Randomization will be performed using a computer software according to patient id. After the randomization, patients will be invited for baseline evaluation that will include full review of their medical status and complete physical examination.

All patients will go through evaluation of their neurocognitive function using further neurocognitive testing battery, questionnaires and brain imaging (perfusion MRI+DTI, SPECT). In cases of brain tumors, skull base tumors, encephalomalacia findings in MRI, patients will be excluded.

The patients in the treated group will be evaluated three time - at baseline, after 3 months of HBOT treatment and after another consequent 3 months period from treatment (6 months from baseline). The patients of the cross group will be evaluated three times as well- at baseline, after 3 month control period without hyperbaric treatment and after a consequent 3 month period of HBOT treatment.

The following HBOT treatment protocol will be practiced: The patients will go through 60 HBOT treatments (each treatment session will be given on a separate day), distributed over three months (five days a week). Each session will be for 60 minutes in 100% oxygen atmosphere and at pressure of 1.5 ATA.

02

Conditions studied

  • Hyperbaric Oxygen Therapy
  • Traumatic Brain Injury
  • Post-Concussion Syndrome

Browse trials for

Keywords

  • HBOT
  • TBI
  • pediatrics
  • PCS
  • PPCS
  • concussion
  • traumatic brain injury
  • hyperbaric oxygen
03

In context

Post-Concussion Syndrome Reclassified

141 studies on the registry are indexed under Post-Concussion Syndrome; 34 are open to participants now.

This study's enrollment of 52 is close to the median of 52 across 114 interventional studies indexed under Post-Concussion Syndrome.

Browse Post-Concussion Syndrome studies →

Lead sponsor

Assaf-Harofeh Medical Center is the lead sponsor of 267 studies on the registry; 43 are open to participants now.

Compared within Post-Concussion Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Injuries, Traumatic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • - Ages 8-15
  • Mild TBI (defined as loss of consciousness with duration of 0-30 minutes, post-traumatic amnesia with duration of less than 24 hours, Glasgow Coma Scale grade of 13-15) within 6 months-3 years prior to the inclusion in the study.
  • Moderate TBI -Patients with a GCS of 9-12 a as well as additional criteria such as CT abnormalities and admission to hospital
  • Presence of at least two PCS as measured by the Post-Concussion Symptom Inventory )see attached) (there's a RCT now recruitingwith at least 1 and not 2) for at least 3 months.
  • No change in cognitive or behavioral functions during one month prior to the beginning of the study (according to parents/teachers report).

Screening protocol:

After signing the (signed by the parents), patients will undergo computerized cognitive tests using the computerized Neurotrax in patients over 10, and standard pen and paper cognitive tests in patients under 10. Patients who fulfill inclusion criteria will be included in the study.

Inclusion criteria:

- Objective cognitive impairment: a decrease of at least 1 standard deviation (SD) from same age mean score in one or more of the following indices : memory, attention, information processing speed, executive functions in both Neurotrax

Exclusion Criteria:

  • - Dynamic neurologic improvement or worsening during the past month (according to parents/teachers report);
  • Had been treated with HBOT for any other reason prior to their inclusion;
  • Chest pathology incompatible with pressure changes (including asthma)
  • Inner ear disease;
  • Claustrophobia;
  • Inability to perform awake brain MRI test
  • Previous neurologic conditions (eg. Epilepsy, neuromuscular diseases, metabolic diseases, etc.)
  • Brain tumors
  • Skull base fractures
  • Active
  • s/p neurosurgery that included: ventricular drainage, subdural hematomas drainage, epidural hematomas drainage, intracerebral hemorrhage evacuation. Depressed fracture surgery, won't be excluded.
  • Encephalomalacia per MRI imaging
  • No informed consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Hyperbaric oxygen therapy

    60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour. 1 meter per minute compression and decompression.

    Device: Hyperbaric oxygen therapy

  • Sham comparator
    Normobaric air SHAM

    60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour. 1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment

    Device: Normobaric air SHAM

Interventions

  • DeviceHyperbaric oxygen therapy

    60 HBOT sessions at 2 ATA 100% oxygen

  • DeviceNormobaric air SHAM

    60 sessions at 1 ATA 21% oxygen (air)

06

What researchers measure

Primary outcomes

  1. Cognitive function

    General,Attention, Memory, Executive functions, Visual spatial and Verbal memory indices Index (scale 0-100) will be measured using the computerized standardized Neurotrax battery test. Each of above cognitive indices is computed as a normalized combined score of 2-3 cognitive tests. (At baseline, this battery will be conducted as part of the screening in patients over 10).

    Time frame: at 3 months

  2. Cognitive function

    General,Attention, Memory, Executive functions, Visual spatial and Verbal memory indices Index (scale 0-100) will be measured using the computerized standardized Neurotrax battery test. Each of above cognitive indices is computed as a normalized combined score of 2-3 cognitive tests. (At baseline, this battery will be conducted as part of the screening in patients over 10).

    Time frame: at 6 months

Secondary outcomes

  1. Post concussion syndrome symptoms

    Patients and their parents will fill questionaries' Postconcussion Symptom Inventory (PCSI) (scale 0-21) at baseline and at their second and/or third evaluations

    Time frame: baseline, 3 months and 6 months from baseline

  2. Health Behaviour inventory

    Patients and their parents will fill questionaries' Health Behaviour inventory (scale 50-200) at baseline and at their second and/or third evaluations

    Time frame: baseline, 3 months and 6 months from baseline

  3. Balance

    Patients will undergo balance tests (BERG Balance Scale) (scale 0-56) at each of the evaluations

    Time frame: baseline, 3 months and 6 months from baseline

  4. Brain functional imaging

    Patients will undergo photon emission tomography (PET-CT) using FDG at each of the three evaluations

    Time frame: baseline, 3 months

  5. Brain microstructural imaging

    Imaging will be conducted in using a 3 Tesla system (Siemens, Germany). The MRI protocol includes the following sequences: Axial T1, T2, FLAIR, Axial Diffusion weighted, Axial T1-PostGadollinium , dynamic contrast enhancement (DSC), diffusion tensor imaging (DTI)

    Time frame: baseline, 3 months and 6 months from baseline

  6. Brain perfusion

    Imaging will be conducted in using a 3 Tesla system (Siemens, Germany). The MRI protocol includes the following sequences: Axial T1, T2, FLAIR, Axial Diffusion weighted, Axial T1-PostGadollinium , dynamic contrast enhancement (DSC), diffusion tensor imaging (DTI)

    Time frame: baseline, 3 months and 6 months from baseline

  7. Short form health survey (PedsQL)

    Patients and their parents will complete questionnaires Pediatric Quality of Life inventory (PedsQL) - multi-dimensional concept that includes domains related to physical, mental, emotional, and social functioning.

    Time frame: baseline, 3 months and 6 months from baseline

  8. Brain network analysis

    Patients will undergo resting state EEG as well as EEG during performing cognitive tasks ,using a 64 electrodes cap.

    Time frame: baseline, 3 months and 6 months from baseline

  9. Behaviour

    The parents and their teachers will complete the following questionnaire at baseline and at their second and/or third evaluations. The rating scales are available for parent (Conners 3-P), teacher (Conners 3-T) and self-report (Conners 3-SR).Subscales include inattention, hyperactivity/impulsivity, learning, executive functioning, aggression and peer relations, as well as subscales mapping onto DSM-IV criteria for ADHD (inattentive), ADHD (hyperactive-impulsive), ADHD combined, Conduct Disorder, and Oppositional-Defiant Disorder. Means and standard deviations for the global index vary dependent on age (for 6 year-olds the mean is 5.15 with a standard deviation of 3.97; means for 17 to 18 year-olds are 3.90 with a standard deviation of 4.00). Raw scores are usually converted to T-scores or percentile scores relative to normative data. T-scores above 60 (percentiles above 84) are considered clinically significant.

    Time frame: baseline, 3 months and 6 months from baseline

  10. Executive functions

    The parents and their teachers will complete the Behavior Rating Inventory of Executive Function(BRIEF) questionnaire at baseline and at their second and/or third evaluations. he Global Executive Composite (GEC) is an overarching summary score that incorporates all of the BRIEF clinical scales. The possible range of scores for teachers is 0 to 24.

    Time frame: baseline, 3 months and 6 months from baseline

07

Study locations

1 site
  • Assaf-Harofeh Medical Center
    Ẕerifin, 70300, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2021, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2017
First posted
Nov 13, 2017
StartActual
Nov 1, 2017
Primary completionActual
Nov 1, 2021
CompletionActual
May 20, 2022
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03339037
Responsible party
Shay Efrati (Prof., Assaf-Harofeh Medical Center) — Principal investigator
First posted
Nov 13, 2017
Start date
Nov 1, 2017
Primary completion
Nov 1, 2021
Completion
May 20, 2022
Last update
Apr 22, 2026

Study contacts

Shai a Efrati, MD
principal investigator · Asaf-Harofhe MC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion